Bliss GVS Pharma hits 52-week high on WHO approval and strong earnings

Bliss GVS Pharma hits 52-week high on WHO approval and strong earnings — Shares of Bliss GVS Pharma surged to a 52-week high of ₹447 following WHO's approval of its manufacturing facility. The stock rallied on the back of strong quarterly earnings and positive sentiment from a recent acquisition. Investors are optimistic about expanded global market access and future revenue growth.
📊 STOCKS: BLISSGVS | 🏢 SECTOR: Pharma | #HIGHIMPACT #Pharma